Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News Evolus Inc EOLS

Healthcare Drug Manufacturers - Specialty & Generic
Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid... see more

Recent & Breaking News (NDAQ:EOLS)

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire 1 day ago

Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2025 Net Revenue

Business Wire January 9, 2026

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire November 14, 2025

Evolus Reports Third Quarter 2025 Financial Results

Business Wire November 5, 2025

Evolus to Participate in 2025 Stifel Healthcare Conference

Business Wire October 28, 2025

Evolus to Report Third Quarter Financial Results on November 5, 2025

Business Wire October 22, 2025

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire October 10, 2025

Top Miami Plastic Surgeon Dr. Benjamin Eskenazi Named Lead Consultant for Evolus' Evolysse(TM) Filler Launch

PR Newswire September 22, 2025

Evolus Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire September 12, 2025

Evolus Announces the Appointment of Tatjana Mitchell as Chief Financial Officer

Business Wire September 8, 2025

Evolus Announces Positive Data From Pivotal Trial for Evolysse(TM) Sculpt Injectable Hyaluronic Acid Gel Product at 2025 Cosmetic Bootcamp

Business Wire August 25, 2025

Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for Evolysse(TM) Sculpt Injectable Hyaluronic Acid Gel Product

Business Wire August 20, 2025

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire August 8, 2025

Evolus Reports Second Quarter 2025 Financial Results and Provides Business Updates

Business Wire August 5, 2025

Evolus Announces Publication of Independent Study in JAMA Dermatology Demonstrating Jeuveau® as a Top Performer Among Leading Neurotoxins

Business Wire July 31, 2025

Evolus to Report Second Quarter Financial Results on August 5, 2025

Business Wire July 22, 2025

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire July 11, 2025

Evolus Expands Global Footprint with Introduction of Nuceiva® (botulinum toxin type A) in France

Business Wire July 9, 2025

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire June 13, 2025

Evolysse(TM) Recognized in 2025 Shape Skin Awards

Business Wire June 10, 2025

Podcasts